ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome — Recruiting • Phase I / Phase II • NCT05419492.
- ETX101 gene therapy trial testing safety and effectiveness in infants and children with Dravet syndrome.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to